Eduardo H Garin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4359331/publications.pdf

Version: 2024-02-01

46 papers 2,303 citations

304743 22 h-index 233421 45 g-index

56 all docs

56
docs citations

56 times ranked 1439 citing authors

| # | Article | IF | CITATIONS |
|----------------------|--|-------------------|---------------------|
| 1 | Benefit of B7-1 staining and abatacept for treatment-resistant post-transplant focal segmental glomerulosclerosis in a predominantly pediatric cohort: time for a reappraisal. Pediatric Nephrology, 2023, 38, 145-159. | 1.7 | 12 |
| 2 | Primary vesicoureteral reflux; what have we learnt from the recently published randomized, controlled trials?. Pediatric Nephrology, 2019, 34, 1513-1519. | 1.7 | 22 |
| 3 | Renal tubular markers as screening tools for severe vesicoureteral reflux. European Journal of Pediatrics, 2019, 178, 525-531. | 2.7 | 15 |
| 4 | Urinary CD80: a biomarker for a favorable response to corticosteroids in minimal change disease. Pediatric Nephrology, 2018, 33, 1101-1103. | 1.7 | 6 |
| 5 | BK viruria and viremia in children with systemic lupus erythematosus. Pediatric Rheumatology, 2017, 15, 21. | 2.1 | 9 |
| 6 | Use of C4d as a diagnostic tool to classify membranoproliferative glomerulonephritis. Nefrologia, 2017, 37, 78-86. | 0.4 | 11 |
| 7 | Angiopoietin-like-4 and minimal change disease. PLoS ONE, 2017, 12, e0176198. | 2.5 | 18 |
| 8 | Pathogenesis of proteinuria in idiopathic minimal change disease: molecular mechanisms. Pediatric Nephrology, 2016, 31, 2179-2189. | 1.7 | 35 |
| 9 | Cytokines as Active Factors in Minimal Change Nephrotic Syndrome. , 2016, , 105-140. | | O |
| | | | |
| 10 | Minimal Change Disease. , 2016, , 85-116. | | 0 |
| 10 | Minimal Change Disease., 2016, , 85-116. Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis. Pediatric Nephrology, 2015, 30, 469-477. | 1.7 | 79 |
| | Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis. | 1.7 | |
| 11 | Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis. Pediatric Nephrology, 2015, 30, 469-477. | | 79 |
| 11 12 | Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis. Pediatric Nephrology, 2015, 30, 469-477. The RIVUR study: a review of its findings. Pediatric Nephrology, 2015, 30, 703-706. Rituximab in idiopathic nephrotic syndrome: does it make sense? Pediatric Nephrology, 2014, 29, | 1.7 | 79 14 |
| 11 12 13 | Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis. Pediatric Nephrology, 2015, 30, 469-477. The RIVUR study: a review of its findings. Pediatric Nephrology, 2015, 30, 703-706. Rituximab in idiopathic nephrotic syndrome: does it make sense? Pediatric Nephrology, 2014, 29, 1313-1319. CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: | 1.7 | 79 14 9 |
| 11 12 13 14 | Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis. Pediatric Nephrology, 2015, 30, 469-477. The RIVUR study: a review of its findings. Pediatric Nephrology, 2015, 30, 703-706. Rituximab in idiopathic nephrotic syndrome: does it make sense? Pediatric Nephrology, 2014, 29, 1313-1319. CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance. Pediatric Nephrology, 2014, 29, 1363-1371. Minimal change disease: a dysregulation of the podocyte CD80–CTLA-4 axis? Pediatric Nephrology, | 1.7 1.7 1.7 | 79 14 9 56 |
| 11 12 13 14 | Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis. Pediatric Nephrology, 2015, 30, 469-477. The RIVUR study: a review of its findings. Pediatric Nephrology, 2015, 30, 703-706. Rituximab in idiopathic nephrotic syndrome: does it make sense? Pediatric Nephrology, 2014, 29, 1313-1319. CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance. Pediatric Nephrology, 2014, 29, 1363-1371. Minimal change disease: a dysregulation of the podocyte CD80–CTLA-4 axis? Pediatric Nephrology, 2014, 29, 2333-2340. CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: | 1.7 1.7 1.7 | 79 14 9 56 |

| # | Article | IF | Citations |
|----|--|-----|-----------|
| 19 | CD80, suPAR and nephrotic syndrome in a case of NPHS2 mutation. Nefrologia, 2013, 33, 727-31. | 0.4 | 9 |
| 20 | Minimal change disease in graft versus host disease: a podocyte response to the graft?. Clinical Nephrology, 2013, 80, 469-473. | 0.7 | 10 |
| 21 | Does hydronephrosis predict the presence of severe vesicoureteral reflux?. European Journal of Pediatrics, 2012, 171, 1605-1610. | 2.7 | 7 |
| 22 | Toll-like receptor 3 ligands induce CD80 expression in human podocytes via an NF-ÂB-dependent pathway. Nephrology Dialysis Transplantation, 2012, 27, 81-89. | 0.7 | 99 |
| 23 | What is the purpose of launching the <i>World Journal of Clinical Pediatrics </i> Clinical Pediatrics, 2012, 1, 1. | 2.1 | 0 |
| 24 | Minimal Change Disease: A CD80 podocytopathy?. Seminars in Nephrology, 2011, 31, 320-325. | 1.6 | 44 |
| 25 | Minimal change disease: a "two-hit―podocyte immune disorder?. Pediatric Nephrology, 2011, 26, 645-649. | 1.7 | 90 |
| 26 | Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis. Kidney International, 2010, 78, 296-302. | 5.2 | 160 |
| 27 | Urinary CD80 Excretion Increases in Idiopathic Minimal-Change Disease. Journal of the American Society of Nephrology: JASN, 2009, 20, 260-266. | 6.1 | 165 |
| 28 | Idiopathic Nephrotic Syndrome and Atopy: Is There a Common Link?. American Journal of Kidney Diseases, 2009, 54, 945-953. | 1.9 | 107 |
| 29 | T regulatory cell function in idiopathic minimal lesion nephrotic syndrome. Pediatric Nephrology, 2009, 24, 1691-1698. | 1.7 | 121 |
| 30 | Treatment of systemic hypertension in children and adolescents. Current Opinion in Pediatrics, 2009, 21, 600-604. | 2.0 | 24 |
| 31 | Comparison of ambulatory blood pressure and Task Force criteria to identify pediatric hypertension. Pediatric Nephrology, 2007, 22, 554-558. | 1.7 | 20 |
| 32 | Diagnostic significance of clinical and laboratory findings to localize site of urinary infection. Pediatric Nephrology, 2007, 22, 1002-1006. | 1.7 | 59 |
| 33 | Proteinuria and Fusion of Podocyte Foot Processes in Rats after Infusion of Cytokine from Patients with Idiopathic Minimal Lesion Nephrotic Syndrome. Nephron Experimental Nephrology, 2006, 102, e105-e112. | 2.2 | 13 |
| 34 | Clinical Significance of Primary Vesicoureteral Reflux and Urinary Antibiotic Prophylaxis After Acute Pyelonephritis: A Multicenter, Randomized, Controlled Study. Pediatrics, 2006, 117, 626-632. | 2.1 | 522 |
| 35 | Effect of tumor necrosis factor α and vascular permeability growth factor on albuminuria in rats. Pediatric Nephrology, 2006, 21, 177-181. | 1.7 | 15 |
| 36 | A case of unfulfilled expectations. Cytokines in idiopathic minimal lesion nephrotic syndrome. Pediatric Nephrology, 2006, 21, 603-610. | 1.7 | 85 |

| # | Article | IF | CITATION |
|----|---|-------------|----------|
| 37 | Cytokine mRNA Profile in Lipoid Nephrosis: Evidence for Increased IL-8 mRNA Stability. Nephron, 2002, 91, 620-626. | 1.8 | 13 |
| 38 | Circulating mediators of proteinuria in idiopathic minimal lesion nephrotic syndrome. Pediatric Nephrology, 2000, 14, 872-878. | 1.7 | 40 |
| 39 | Primary vesicoureteral reflux: review of current concepts. Pediatric Nephrology, 1998, 12, 249-256. | 1.7 | 100 |
| 40 | Anti-interleukin 8 antibody abolishes effects of lipoid nephrosis cytokine. Pediatric Nephrology, 1998, 12, 381-385. | 1.7 | 26 |
| 41 | Effect of interleukin-8 on glomerular sulfated compounds and albuminuria. Pediatric Nephrology, 1997, 11, 274-279. | 1.7 | 34 |
| 42 | Effect of lipoid nephrosis cytokine on glomerular sulfated compounds and albuminuria. Pediatric Nephrology, 1995, 9, 587-593. | 1.7 | 15 |
| 43 | IL-8 production by peripheral blood mononuclear cells in nephrotic patients. Kidney International, 1994, 45, 1311-1317. | 5. 2 | 71 |
| 44 | Effect of Supernatants from Nephrotic Peripheral Blood Mononuclear Cells on 35Sulfate Incorporation in Rat Glomerular Basement Membrane. Pediatric Research, 1985, 19, 836-840. | 2.3 | 11 |
| 45 | Renal Growth and Scarring in Kidneys with Reflux and a Concentrating Defect. Journal of Urology, 1983, 129, 784-786. | 0.4 | 13 |
| 46 | Glomerular and Tubular Function in Children with Ileal Conduit Urinary Diversion. Journal of Urology, 1977, 117, 505-507. | 0.4 | 4 |